**Author details**

Niknam Riyahi1,2,3, M. Reza Saadatzadeh1,3,4,5, Khadijeh Bijangi-Vishehsaraei1,5, Farinaz Barghi1,3,6, Pankita H. Pandya1,3,4,5,6 and Karen E. Pollok1,2,3,4,5,6\*

1 Department of Pediatrics, Herman B Wells Center for Pediatric Research, United States

2 Department of Pharmacology and Toxicology, United States

3 Indiana University School of Medicine, Indiana University, Indianapolis, IN, 46202, United States

4 Indiana University Simon Comprehensive Cancer Center, United States

5 Division of Hematology/Oncology, Riley Hospital for Children, Indianapolis, IN, 46202, USA

6 Department of Medical and Molecular Genetics, United States

\*Address all correspondence to: kpollok@iu.edu

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**157**

101-110

*DNA Repair Defects in Sarcomas*

**References**

Reviews Cancer. 2020:1-16

[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;**69**(1):7-34

[3] Reed DR, Naghavi A, Binitie O. Sarcoma as a model for adolescent and young adult care. Journal of oncology

practice. 2019;**15**(5):239-247

[4] Nathenson MJ, Conley AP,

2018;**23**(1):71

p. 128-41.

Sausville E. Immunotherapy: a new (and old) approach to treatment of soft tissue and bone sarcomas. The oncologist.

[5] Hatina J, Kripnerova M, Houfkova K,

Pesta M, Kuncova J, Sana J, et al. Sarcoma stem cell heterogeneity. Stem Cells Heterogeneity-Novel Concepts:

[6] O'Connor MJ. Targeting the DNA damage response in cancer. Molecular

[7] Ferrari A, Dirksen U, Bielack S. Sarcomas of soft tissue and bone. Tumors in Adolescents and Young Adults. 43: Karger Publishers; 2016.

[8] Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert review of anticancer therapy. 2018;**18**(1):39-50

[9] Schaefer I-M, Cote GM, Hornick JL. Contemporary sarcoma diagnosis, genetics, and genomics. Journal of Clinical Oncology. 2018;**36**(2):

[10] Oda Y, Yamamoto H, Kohashi K, Yamada Y, Iura K, Ishii T, et al. Soft tissue sarcomas: From a

Springer; 2019. p. 95-118.

Cell. 2015;**60**(4):547-560

*DOI: http://dx.doi.org/10.5772/intechopen.94881*

[1] Nacev BA, Jones KB, Intlekofer AM, Jamie S, Allis CD, Tap WD, et al. The epigenomics of sarcoma. Nature

morphological to a molecular biological approach. Pathology International.

[11] Skubitz KM, D'Adamo DR, editors. Sarcoma. Mayo Clinic Proceedings;

[12] Sakthivel KM, Hariharan S. Regulatory players of DNA damage repair mechanisms: Role in Cancer Chemoresistance. Biomedicine & Pharmacotherapy. 2017;**93**:1238-1245

[13] Turgeon M-O, Perry NJ,

[14] Klinakis A, Karagiannis D, Rampias T. Targeting DNA repair in cancer: Current state and novel approaches. Cellular and Molecular Life

Sciences. 2020;**77**(4):677-703

cancer biology; 2019: Elsevier.

medicine. 2014;46(7):e106-e.

[17] Di Maso V, Mediavilla MG, Vascotto C, Lupo F, Baccarani U, Avellini C, et al. Transcriptional up-regulation of APE1/Ref-1 in hepatic tumor: role in hepatocytes resistance to oxidative stress and apoptosis. PLoS

One 2015;10(12):e0143289.

[18] Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Current opinion in pharmacology. 2008;**8**(4):363-369

[16] Thakur S, Sarkar B, Cholia RP, Gautam N, Dhiman M, Mantha AK. APE1/Ref-1 as an emerging therapeutic target for various human diseases: phytochemical modulation of its functions. Experimental & molecular

[15] Motegi A, Masutani M, Yoshioka K-i, Bessho T, editors. Aberrations in DNA repair pathways in cancer and therapeutic significances. Seminars in

oncology. 2018;**8**:15

Poulogiannis G. DNA damage, repair, and cancer metabolism. Frontiers in

2017;**67**(9):435-446

2007: Elsevier.
